You are here: Industry Insights > favipiravir

News List

Glenmark announces top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment expresspharma
July 23, 2020
The study evaluated the efficacy and safety of favipiravir plus standard supportive care, versus standard supportive care alone, in mild to moderate patients of COVID-19.
Biophore ramps up Made-In-India Favipiravir production for Covid-19 expresspharma
July 15, 2020
Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well.
Glenmark Pharma cuts price of COVID-19 drug by 27 pc to Rs 75/tablet expresspharma
July 14, 2020
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.
Glenmark set to get manufacturing and marketing approval for favipiravir expresspharma
June 22, 2020
Sources inform that SEC has recommended the grant of permission, along with some recommendations, the company plans to launch its product early next week.
Optimus launches COVID-19 drug Favipiravir, commences commercial export expresspharma
June 19, 2020
The drug is being marketed under the brand name Favicovid both in India and other countries.
ICT, Lasa succeed in Favipiravir drug synthesis, to commence production expresspharma
June 18, 2020
The collaborators aim to manufacture close to 10,000 doses of the antiviral to begin with.
Local API production in India for COVID-19 repurposed drugs may offer competitive advantage: GlobalData expresspharma
June 08, 2020
The advantages will be in terms of supply and price for the formulations manufactured in India, be it remdesivir, favipiravir or hydroxychloroquine (HCQ).
Indian pharma companies looking to leverage opportunities in drug repurposing: GlobalData expresspharma
June 03, 2020
The Drug Controller General of India (DCGI) has recently given approval to Indian pharma companies Glenmark and Strides Pharma Science to initiate clinical trials of favipiravir for COVID-19 patients.
60,000 doses of avifavir, a COVID-19 treatment, to be delivered in June europeanpharmaceuticalreview
June 02, 2020
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
Appili set to evaluate favipiravir as preventive measure against Covid-19 pharmaceutical-business-review
May 28, 2020
Appili Therapeutics has secured regulatory clearance from Health Canada to move ahead with a phase 2 study for studying FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against the outbreak of novel coronavirus (Covid-19).

Previous page 1 2 3 4 5 6 Next page